• AO/PI Staining Solution: Evidence and Scope

  2026-10-17

  APExBIO describes AO/PI Staining Solution (SKU K2269) as a two-dye fluorescence reagent intended to distinguish cells with apparently intact versus compromised membranes. Acridine orange labels nucleated cells through green fluorescence, while propidium iodide is described as labeling cells with compromised membrane barriers in red. The product information supports a conceptual fluorescence-based cell-counting role, but it does not provide identity-matched study results, effect sizes, validation cohorts, or evidence that the reagent establishes overall cellular function or long-term viability.

• When Context Changes What a Cdc42 Result Means

  2026-10-16

  A Cdc42 result does not carry one fixed biological meaning across models. The kidney-fibrosis study of daphnepedunin A links Cdc42 activity to a renal fibroblast and mouse fibrosis phenotype, whereas supplier-described ZCL278 findings involve motility, neuronal morphology, and biochemical target engagement. These contexts support different levels of inference and should not be treated as interchangeable evidence.

• EZ Cap Mouse IL-7 mRNA: What Is Documented

  2026-10-16

  The product listing identifies an APExBIO item named EZ Cap™ Mouse IL-7 mRNA (m1Ψ, HA tag), SKU R1054, but provides no matched research study or performance data. Its nomenclature supports a limited identity and measurement interpretation; it does not establish sequence details, translation, biological activity, assay performance, or clinical relevance.

• Mdivi-1 and CIH: Reading the Apoptosis Evidence

  2026-10-15

  This study links chronic intermittent hypoxia in mice with pulmonary mitochondrial injury, apoptosis-associated signaling, gut dysbiosis, and altered metabolites. Mdivi-1 improved several of these readouts, but the evidence supports a pharmacological association rather than definitive proof that gut metabolites causally drive lung apoptosis or that DRP1 is the sole relevant target.

• (R)-MG132: Identity, Mechanism, and Evidence Limits

  2026-10-15

  APExBIO describes (R)-MG132 as a stereoisomeric MG-132 variant with markedly reduced inhibition of the 20S proteasome’s chymotrypsin-like activity. Its proposed role is a negative control in ubiquitin-proteasome system research, but the available product description is not a substitute for identity-matched research evidence and does not establish universal cellular inertness.

• Hoechst 33258: Mechanism and Evidence Boundaries

  2026-10-14

  Hoechst 33258 is described by APExBIO as a cell-permeable bis-benzimide DNA stain whose fluorescence increases after preferential minor-groove binding to AT-rich regions of double-stranded DNA. Its reported excitation and emission properties support blue-channel DNA visualization, while its use in cell-cycle analysis should be interpreted as a DNA-content measurement rather than a direct measurement of cell-cycle mechanisms. Because no identity-matched research paper is available here, the product description establishes intended measurement scope and reported physicochemical properties, not independently verified performance, effect sizes, or comparative superiority.

• AO/PI Staining and Diabetic Nephropathy Evidence

  2026-10-14

  AO/PI staining provides a membrane-integrity-based approach to live–dead cell discrimination, but the supplied diabetic nephropathy study does not document use of this reagent. Its findings support a preclinical association between phillygenin, reduced inflammatory and apoptotic markers, and improved kidney injury measures in cell and mouse models—not a clinical treatment conclusion.

• What APEX-RNA-MS Reveals About RNA Neighborhoods

  2026-10-13

  APEX-RNA-MS provides a proximity-based view of modified RNA near selected cellular structures. The cited study reports modification patterns in stress granules, P-bodies, and DNA damage foci, while also showing why proximity signals should not be interpreted as direct binding, transcript-level localization, or proof of biological causation.

• How CD28–ARS2 Splicing Shapes CD8 T-Cell Metabolism

  2026-10-13

  Holling and colleagues report that CD28 signaling promotes ARS2-associated alternative splicing in activated CD8+ T cells, favoring PKM2 over PKM1 and supporting metabolic flexibility, interferon-gamma production, and antitumor effector activity. The findings support a mechanistic model in the studied experimental systems, but they do not establish a clinical intervention or connect Probenecid to this pathway.

• Amiloride (MK-870): Evidence and Boundaries

  2026-10-12

  Amiloride (MK-870) is presented by APExBIO as a research compound for studying epithelial sodium channels, ion transport, and related receptor signaling. The supplied 2026 nanoliposome study concerns a distinct phosphatidylinositol-based vaccine platform and does not establish a role for amiloride in cellular immunity, endoplasmic-reticulum antigen delivery, or tumor vaccination. Accordingly, amiloride’s applicability is best framed as a mechanistic research question rather than a validated therapeutic or nanovaccine component.

• Phillygenin and Diabetic Nephropathy: Study Overview

  2026-10-12

  A source-grounded overview of a 2025 Phytomedicine study examining whether phillygenin protects against diabetic kidney injury through inflammatory and survival signaling. The evidence is promising but remains preclinical, with mechanistic conclusions limited by pathway-marker associations, model scope, and the absence of clinical validation.

• Neuroligin 1 and Social Memory Maintenance

  2026-10-11

  A 2025 mouse study links social-interaction-induced Neuroligin 1 proteolysis in the ventral hippocampus to short-term social-memory maintenance through an intracellular fragment and cofilin signaling. The findings are mechanistically suggestive but remain preclinical and do not establish any role for KN-62 or CaMKII.

• Sulfachloropyridazine: From DHPS to Microbiome

  2026-10-10

  Sulfachloropyridazine is a sulfonamide antibacterial agent whose value extends from DHPS biochemistry to microbiome and metabolome interpretation. This evidence-focused guide explains how to connect enzyme inhibition, antimicrobial phenotypes, and infection-model findings without overstating causality.

• Berbamine Hydrochloride in Ferroptosis Research

  2026-10-09

  A source-grounded overview of berbamine hydrochloride, ferroptosis biology, and the METTL16–SENP3–LTF axis in hepatocellular carcinoma, with emphasis on evidence strength, conceptual applications, and translational limitations.

• Oridonin, Inflammation, and Esophageal Cancer

  2026-10-09

  Peng et al. report that oridonin was associated with reduced inflammatory signaling and improved pathological features in a 4-NQO-induced murine model of esophageal cancer, with particular attention to the TLR4/NF-κB/NLRP3 inflammasome axis. The study offers a mechanistic framework for inflammation-focused oncology research, but its findings remain preclinical and do not establish clinical efficacy or definitive pathway causality.

7959 records 1/531 page Next 12345 下5页 Last page